Chicago, IL 的 黑色素瘤 臨床試驗
15 項針對 黑色素瘤 的研究正在 Chicago（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- 還有 1 項
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
招募中2 期
- University of Illinois Cancer Center, Chicago
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
招募中2 期
- Northwestern University, Chicago
- University of Illinois, Chicago
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
招募中3 期
- Northwestern University, Chicago
- Swedish Covenant Hospital, Chicago
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
招募中1/2 期
- Northwestern University, Chicago
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
招募中1/2 期
- Lurie Children's Hospital-Chicago, Chicago
Project: Every Child for Younger Patients With Cancer
招募中觀察性研究
- Lurie Children's Hospital-Chicago, Chicago
- Northwestern University, Chicago
- University of Illinois, Chicago
- 還有 1 項
Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions
招募中
- Northwestern University, Chicago
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
招募中1/2 期
- Call for Information (Investigational Site 0024), Chicago
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
招募中1/2 期
- University of Chicago Medical Center, Chicago
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
招募中1/2 期
- University of Chicago, Chicago
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
招募中2/3 期
- Northwestern Memorial Hospital, Chicago
- University of Chicago Medical Center, Chicago
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中觀察性研究
- John H Stroger Jr Hospital of Cook County, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中觀察性研究
- Massive Bio SYNERGY-AI site, Chicago
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
招募中
- Advocate Illinois Masonic Medical Center, Chicago
其他城市的 黑色素瘤 試驗
- Houston, TX59 項研究
- New York City, NY38 項研究
- Los Angeles, CA34 項研究
- Nashville, TN33 項研究
- Pittsburgh, PA31 項研究
- Boston, MA26 項研究
- Philadelphia, PA23 項研究
- San Francisco, CA22 項研究
- Durham, NC21 項研究
- Atlanta, GA21 項研究
- St. Louis, MO21 項研究
- Salt Lake City, UT21 項研究
Chicago 的其他研究
- 非小細胞肺癌61 項研究
- 乳癌58 項研究
- 癌症（所有類型）51 項研究
- 轉移性癌症45 項研究
- 前列腺癌45 項研究
- 肥胖症41 項研究
- 肺癌41 項研究
- 卵巢癌36 項研究
- 中風34 項研究
- 大腸直腸癌33 項研究
- 心臟衰竭31 項研究
- 過重28 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月5日。各研究自行設定資格標準；由研究團隊決定參與者資格。